Contact Us
Drug Search Results
More Filters [+]

Tepoditamab

Alternative Names: tepoditamab, mcla-117, mcla117, mcla 117
Latest Update: 2021-05-10
Latest Update Note: Clinical Trial Update

Product Description

Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds CLEC12A on myeloid cells and CD3epsilon on cytotoxic T cells. It is being developed by Merus as a novel therapy for acute myeloid leukemia (AML) . (Sourced from: https://pubchem.ncbi.nlm.nih.gov/substance/384403634#section=Available-Date)

Mechanisms of Action: CLL1 Inhibitor,CD3 Binder

Novel Mechanism: Yes

Modality: Bispecific Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merus N.V.
Company Location: 3584 CM UTRECHT P7 3584 CM
Company CEO: Sven (Bill) Ante Lundberg
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tepoditamab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Acute Myeloid Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
MCLA-117-CL01

P1

Unknown status

Acute Myeloid Leukemia

2021-07-01

28%

Recent News Events

Date

Type

Title

05/14/2020

News Article

 Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program Updates

06/21/2019

News Article

 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market 2019

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions